Viewing Study NCT01857193

Home Icon Home Search Icon Search Certify Doc Icon Certify Doc Certify Doc Icon Genes Certify Doc Icon Clinical Trials Certify Doc Icon CompTox Processes Icon DrugMatrix Open Targets Icon Open Targets Processes Icon Products Support Icon Support Bugs Icon Bugs
Main Search Make This Study a Gene Therapy Make This Study a Not Gene Therapy Report Bug
Ignite Creation Date: 2025-12-25 @ 1:25 AM
Ignite Modification Date: 2026-02-20 @ 12:57 PM
Study NCT ID: NCT01857193
Status: COMPLETED
Last Update Posted: 2021-04-13
First Post: 2013-05-16
Is NOT Gene Therapy: True
Has Adverse Events: False
Brief Title: Phase Ib Trial of LEE011 With Everolimus (RAD001) and Exemestane in the Treatment of Hormone Receptor Positive HER2 Negative Advanced Breast Cancer
Sponsor: Novartis Pharmaceuticals
Organization:
Overview Dates Organization Conditions Design Enrollment Locations Outcomes Modules Raw JSON

Conditions & Keywords Data

Conditions:

Conditions

Condition Brief Condition Text View
None Breast Cancer View
Keywords:

Keywords

Keyword Brief Keyword Text View
None Open label View
None dose escalation View
None ER+ View
None LEE011 View
None CDK4/6 View
None everolimus View
None advanced breast cancer View
None mTOR View
None HR positive View
None HER2 negative View